Journal Home
Search for

Volume 165, Issue 2, Pages 135-143 (March 2006)


View previous. 8 of 17 View next.

SATR-1 hypomethylation is a common and early event in breast cancer

Fabrício F. Costaa, Valeria A. Paixãoa, Felicia P. Cavalhera, Karina B. Ribeirob, Isabela W. Cunhac, José Augusto Rinck Jr.d, Michael O'Haree, Alan Mackayf, Fernando A. Soaresc, Ricardo R. Brentania, Anamaria A. CamargoaCorresponding Author Informationemail address

Received 16 March 2005; received in revised form 15 July 2005; accepted 21 July 2005.

Abstract 

Genome stability and normal gene expression are maintained by a fixed and predetermined DNA methylation pattern, which becomes abnormal in malignant cells. Hypomethylation of satellite DNA sequences is frequently found in tumors and has been associated with an increased frequency of DNA rearrangements and chromosome instability. In this work, we used methylation-sensitive arbitrarily primed polymerase chain reaction (MSAP-PCR) to identify differentially methylated DNA fragments in normal and tumor breast samples. We identified a novel differentially methylated fragment located on chromosome 5 with high similarity to a SATR-1 satellite sequence. This fragment was found to be hypomethylated in 63% of breast tumor cell lines and in 86% of breast tumors relative to normal breast tissue. We found that normal tissue adjacent to breast tumors displayed a variable decrease in methylation and that the decrease observed for most of these adjacent samples was higher than observed for normal breast tissue derived from reduction mammoplasty. The methylation decrease was, however, significantly higher in tumor samples than in adjacent tissue (χ2 = 154, 1 df, P < 10−4), suggesting that SATR-1 hypomethylation frequently occurs in the early stages of tumor development. Our results highlight the importance of global DNA hypomethylation as a contributing factor in breast tumorigenesis.

a Laboratory of Molecular Biology and Genomics, Ludwig Institute for Cancer Research, Rua Prof. Antonio Prudente, 109, 4th floor, 01509-010 São Paulo, SP Brazil

b Cancer Hospital Registry, Hospital A.C. Camargo, 01509-010 São Paulo, SP, Brazil

c Pathology Department, Hospital A.C. Camargo, 01509-010 São Paulo, SP, Brazil

d Clinical Oncology Department, Hospital A.C. Camargo, 01509-010 São Paulo, SP, Brazil

e Breast Cancer Laboratory, Ludwig Institute for Cancer Research, University College London Medical School, W1W 7EJ, London, UK

f The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, SW36JB, London, UK

Corresponding Author InformationCorresponding author. Tel.: +55-11-3388-3248; fax: +55-11-3207-7001.

PII: S0165-4608(05)00492-9

doi:10.1016/j.cancergencyto.2005.07.023


View previous. 8 of 17 View next.